INCLIVA

Experimental Compound Shows Promise for Myotonic Dystrophy Type 1 Treatment, Advances to Clinical Trial

- Researchers at the University of Valencia have developed a new generation of compounds that successfully reverse molecular defects in myotonic dystrophy type 1, demonstrating measurable improvements in muscle strength and stiffness in experimental models. - The treatment targets dysregulated cellular regulators that contribute to impaired muscle function, representing a novel therapeutic approach that had not been previously exploited for this genetic disease. - The promising preclinical results have led to the launch of the arthemiR clinical trial through Arthex Biotech, marking the first evaluation of this therapeutic approach in patients with myotonic dystrophy type 1. - The compounds demonstrate particularly strong capacity to reach muscle tissue, addressing one of the main challenges in developing therapies for neuromuscular diseases.